Biohaven Ltd
BHVN15.110USD
+1.750+13.10%
收盤 07/17, 16:00（美東）報價延遲15分鐘
1.54B總市值
虧損本益比TTM
關於 Biohaven Ltd 公司
Biohaven Ltd. 是一家臨牀階段的生物製藥公司。該公司專注於發現、開發和商業化關鍵治療領域的治療方法，包括免疫學、神經科學和腫瘤學。其臨牀和臨牀前項目包括用於治療癲癇和情緒障礙的 Kv7 離子通道調節；用於治療免疫疾病的細胞外蛋白質降解；用於治療偏頭痛和神經性疼痛的瞬時受體電位黑素 3 (TRPM3) 拮抗劑；用於治療神經炎症疾病的酪氨酸激酶 2/Janus 激酶 1 (TYK2/JAK1) 抑制；用於治療強迫症 (OCD) 和脊髓小腦共濟失調 (SCA) 的穀氨酸調節；用於治療神經肌肉和代謝疾病（包括脊髓性肌萎縮症 (SMA) 和肥胖症）的肌生長抑制素抑制；以及用於治療癌症的抗體募集、雙特異性分子和抗體藥物偶聯物 (ADC)。 Troriluzole 是一種新化學實體 (NCE)，是活性代謝物利魯唑的三肽前體藥物。
公司簡介
公司代碼BHVN
公司名稱Biohaven Ltd
上市日期Sep 23, 2022
成立日期2022
CEODr. Vlad Coric, M.D.
員工數量256
證券類型Ordinary Share
年結日Sep 23
公司地址215 Church Street
城市NEW HAVEN
上市交易所NYSE Consolidated
國家United States of America
郵編06510
電話12034040410
網址https://www.biohaven.com/
公司代碼BHVN
上市日期Sep 23, 2022
成立日期2022
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Mr. Kishen (Kishan) Mehta
Mr. Kishen (Kishan) Mehta
Director
Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月14日 週三
更新時間: 5月14日 週三
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
37.06%
Investment Advisor
28.02%
Hedge Fund
18.28%
Individual Investor
11.53%
Private Equity
2.88%
Research Firm
2.07%
Sovereign Wealth Fund
0.88%
Bank and Trust
0.64%
Venture Capital
0.51%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
560
104.96M
102.79%
-7.46M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
2023Q1
331
78.42M
114.97%
+3.79M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
8.40M
8.23%
+4.76K
+0.06%
Mar 31, 2025
1919 Investment Counsel, LLC
6.59M
6.46%
+34.44K
+0.53%
Mar 31, 2025
Childs John W
6.51M
6.38%
+351.58K
+5.71%
Mar 10, 2025
Janus Henderson Investors
6.44M
6.3%
-544.20K
-7.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
6.19%
-61.68K
-0.97%
Mar 31, 2025
Suvretta Capital Management, LLC
5.62M
5.5%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.81M
4.71%
+385.00K
+8.69%
Mar 31, 2025
State Street Global Advisors (US)
3.42M
3.35%
-90.13K
-2.57%
Mar 31, 2025
Coric (Vladimir)
3.18M
3.11%
+26.57K
+0.84%
Mar 10, 2025
RP Management, LLC
2.94M
2.88%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 7月6日 週日
更新時間: 7月6日 週日
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
2.32%
Roundhill GLP-1 & Weight Loss ETF
1.24%
Simplify Health Care ETF
1.16%
Global X Guru Index ETF
1.15%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Tema Neuroscience and Mental Health ETF
0.56%
SPDR S&P Biotech ETF
0.45%
WisdomTree BioRevolution Fund
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Main Thematic Innovation ETF
0.23%
查看更多
iShares Neuroscience and Healthcare ETF
佔比2.32%
Roundhill GLP-1 & Weight Loss ETF
佔比1.24%
Simplify Health Care ETF
佔比1.16%
Global X Guru Index ETF
佔比1.15%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.85%
Tema Neuroscience and Mental Health ETF
佔比0.56%
SPDR S&P Biotech ETF
佔比0.45%
WisdomTree BioRevolution Fund
佔比0.3%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.26%
Main Thematic Innovation ETF
佔比0.23%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
